Vazyme(SH:688105) Xin Lang Cai Jing·2025-11-12 01:36Summary of Key Points Core Viewpoint - NuoVaxan's stock performance and financing activities indicate a mixed sentiment among investors, with a notable decrease in revenue and net profit year-on-year, suggesting potential challenges ahead for the company [1][2]. Group 1: Stock Performance and Financing - On November 11, NuoVaxan's stock rose by 0.17% with a trading volume of 36.08 million yuan [1]. - The financing buy-in amount for NuoVaxan on the same day was 3.48 million yuan, while the financing repayment was 4.09 million yuan, resulting in a net financing outflow of 610,400 yuan [1]. - As of November 11, the total financing and securities lending balance for NuoVaxan was 94.44 million yuan, with the financing balance at 93.64 million yuan, accounting for 0.99% of the circulating market value, indicating a high level compared to the past year [1]. Group 2: Company Overview and Financial Performance - NuoVaxan, established on March 16, 2012, and listed on November 15, 2021, specializes in the research and development of functional proteins and high molecular organic materials, with a focus on biological reagents and in vitro diagnostics [2]. - The company's revenue composition includes 81.86% from biological reagents, 9.99% from diagnostic reagents, 3.15% from consumables, 2.96% from equipment, 1.85% from technical services, and 0.18% from other sources [2]. - For the period from January to September 2025, NuoVaxan reported a revenue of 952 million yuan, a year-on-year decrease of 3.40%, and a net profit attributable to shareholders of 6.62 million yuan, down 63.57% year-on-year [2]. Group 3: Dividend Information - Since its A-share listing, NuoVaxan has distributed a total of 731 million yuan in dividends, with 611 million yuan distributed over the past three years [3].